These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3110 related items for PubMed ID: 28434399

  • 1. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A, Burns TF.
    J Hematol Oncol; 2017 Apr 24; 10(1):87. PubMed ID: 28434399
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y, Gao M, Huang Z, Yu J, Meng X.
    J Hematol Oncol; 2020 Jul 28; 13(1):105. PubMed ID: 32723363
    [Abstract] [Full Text] [Related]

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 7. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B, Campo MJ, Gainor JF.
    Oncologist; 2017 Jan 01; 22(1):81-88. PubMed ID: 27534574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M, Rouquette I, Adam J, Cortot A, Cazes A, Gibault L, Damotte D, Lantuejoul S.
    Ann Pathol; 2017 Feb 01; 37(1):61-78. PubMed ID: 28162296
    [Abstract] [Full Text] [Related]

  • 14. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T, Gray JE, Antonia SJ.
    Expert Opin Biol Ther; 2017 Mar 01; 17(3):305-312. PubMed ID: 28064556
    [Abstract] [Full Text] [Related]

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
    Zibelman M, Ramamurthy C, Plimack ER.
    Urol Oncol; 2016 Dec 01; 34(12):538-547. PubMed ID: 27888981
    [Abstract] [Full Text] [Related]

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 156.